Home

Role of hypoxemia in formation of upper limb muscle dysfunction in case of chronic obstructive lung disease

13 April 2011
Written by Sukhanova G.I., Kinyaikin M.F., Rassokhina N.Yu., Kramar A.V.

  UDK: 616.24‑007.271‑036.12:612.127.2:616.747‑009.1 | Pages: 90–92 | Read full textDownload PDF 

Annotation:

The authors have analysed muscular strength of upper limbs depending on hypoxemia and cardiac pathology in 68 patients with chronic obstructive lung disease aged 42 to 77 years and found out that the muscular dysfunction was more evident among the patients diagnosed with hypox‑emia than among those without hypoxemia. The associated cardiovascular pathology aggravated the‑se affections. The authors consider the proper administration of oxygen therapy is of great importance to eliminate hypoxemia and prevent skeletal muscles dysfunction in patients diagnosed with chronic obstructive lung disease.

Links to authors:

G.I. Sukhanova, M.F. Kinyaikin
Vladivostok State Medical University (2 Ostryakova Av. Vladivostok 690950 Russian Federation)
N.Yu. Rassokhina
Vladivostok Branch of Far Eastern Scientific Centre of Physiology and Pathology of Breathing of the Siberian Branch of RAMS – Research Institute of Medical Climatology and Restorative Treatment (73g Russkaya St. Vladivostok 690105 Russian Federation)
A.V. Kramar
Far Eastern Regional Medical Centre of the Federal Medical Bio-logical Agency of Russia (161 100 Year Anniversary of Vladivostok Av. Vladivostok 690022 Russian Federation)

  1. Avdeev S.N. Chronic obstructive pulmonary disease as a systemic
    inflammatory, Hronicheskaja obstruktivnaja bolezn legkih / ed.
    A.G. Chuchalin. M.: Atmosfera, 2008. P. 131–149.
    2. Kinjajkin M.F., Suhanova G.I., Besednova N.N., Kuznecova T.A.
    Role of hypoxemia and systemic inflammation in the forma‑
    tion of pulmonary hypertension and chronic pulmonary heart
    disease in patients with chronic obstructive pulmonary disease,
    Dalnevostochnyj med. zhurnal. 2010. No. 1. P. 6–8.
    3. Agusti A.G.N., Noguera A., Sauleda J. et al. Systemic effects of
    chronic obstructive pulmonary disease // Eur. Respir. J. 2003.
    Vol. 21. P. 347–360.
    4. Anthonisen N.R., Connett J.E., Enright P.L., Man‑
    freda J. Lung health study research group. Hospital‑
    izations and mortality in the lung health study, Amer.
    J. Respir. Crit. Care Med. 2002. Vol. 166. P. 333–339.
    5. Barnes P.J., Celli B.R. Systemic manifestations and
    comorbidities of COPD, Eur. Respir. J. 2009.Vol.
    33. P. 1165–1185.
    6. Decramer M., De Benedetto F., Del Ponte A.,
    Marinari S. Systemic effects of COPD, Respir. Med.
    2005. Vol. 99. P. S3–S10.
    7. Di Francia M., Barbier D., Mege J.L., Orehek J. Tu‑
    mor necrosis factor‑alpha levels and weight loss in
    chronic obstructive pulmonary disease, Amer. J. Respir. Crit. Care Med. 1994. Vol. 150. P. 1453–1455.
    8. Jagoe R.T., Engelen M.P. Muscle wasting and
    changes in muscle protein metabolism in chron‑
    ic obstructive pulmonary disease, Eur. Respir. J.
    Suppl. 2003. Vol. 46. P. 52–63.
    9. Jakobsson P., Jorfeldt L., Brundin A. Skeletal muscle metabolites
    and fibre types in patients with advanced chronic obstructive
    pulmonary disease (COPD), with and without chronic respira‑
    tory failure, Eur. Respir. J. 1990. Vol. 3. P. 192–196.
    10. Jarratt J.A., Morgan C.N., Twomey J.A. et al. Neuropathy in chron‑
    ic obstructive pulmonary disease: a multicentre electrophysiologi‑
    cal and clinical study, Eur. Respir. J. 1992. Vol. 5. P. 517–524.
    11. Joppa P., Petrasova D., Stancak В., Tkacova R. Systemic inflamma‑
    tion in patients with COPD and pulmonary hypertension, Chest.
    2006. Vol. 130. P. 326–333.
    12. Sin D.D., Man S.F Why arc patients with chronic obstructive
    pulmonary disease at increased risk of cardiovascular diseases?
    The potential role of systemic inflammation in chronic obstruc‑
    tive pulmonary disease, Circulation. 2003. Vol. 107. P. 1514–1519.
    13. Sin D.D., Wu L., Man S.F. The relationship between reduced lung
    function and cardiovascular mortality: a population‑based study and
    a systematic review of the literature, Chest. 2005. Vol. 127. P. 1952–1959.
    14. Suggett A.J., Jarratt J.A., Proctor A., Howard P. Almitrine and
    peripheral neuropathy, Lancet. 1985. No. 2 (8459). P. 830–831.
    15. Takabatake N., Nakamura H., Minamihaba O. et al. A novel
    pathophysiologic phenomenon in cachexic patients with chronic
    obstructive pulmonary disease: the relationship between the cir‑
    cadian rhythm of circulating leptin and the very low‑frequency
    component of heart rate variability, Amer. J. Respir. Crit. Care
    Med. 2001. Vol. 163. P. 1314–1319. 

PUBLISHER: "MEDITSYNA DV"

Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.